S M Gryaznov

Summary

Affiliation: Geron Corporation
Country: USA

Publications

  1. ncbi Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors
    Brittney Shea Herbert
    Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas, TX 75390 9039, USA
    Oncogene 21:638-42. 2002
  2. ncbi Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells
    Z Gunnur Dikmen
    Faculty of Medicine, Department of Biochemistry, University of Hacettepe, Ankara, Turkey
    J Cell Biochem 104:444-52. 2008
  3. pmc RNA mimetics: oligoribonucleotide N3'-->P5' phosphoramidates
    S M Gryaznov
    Lynx Therapeutics Inc, 3832 Bay Center Place, Hayward, CA 94545, USA
    Nucleic Acids Res 26:4160-7. 1998
  4. ncbi Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent
    Sergei M Gryaznov
    Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA
    Nucleosides Nucleotides Nucleic Acids 26:1577-9. 2007
  5. doi Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents
    Sergei M Gryaznov
    Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA
    Chem Biodivers 7:477-93. 2010
  6. ncbi Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents
    Sergei Gryaznov
    Geron Corporation, Menlo Park, California 94025, USA
    Nucleosides Nucleotides Nucleic Acids 22:577-81. 2003
  7. ncbi Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents
    S M Gryaznov
    Geron Corporation, Menlo Park, CA 94025, USA
    Biochim Biophys Acta 1489:131-40. 1999
  8. ncbi Novel short oligonucleotide conjugates as inhibitors of human telomerase
    Krisztina Pongracz
    Geron Corporation, Menlo Park, California 94025, USA
    Nucleosides Nucleotides Nucleic Acids 22:1627-9. 2003
  9. pmc New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
    Rintaro Hashizume
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Neuro Oncol 10:112-20. 2008
  10. ncbi Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase
    Shalmica R Jackson
    Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Cancer Res 67:1121-9. 2007

Collaborators

Detail Information

Publications14

  1. ncbi Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors
    Brittney Shea Herbert
    Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas, TX 75390 9039, USA
    Oncogene 21:638-42. 2002
    ..The results suggest that the oligonucleotide N3'-->P5' phosphoramidates, and particularly thio-phosphoramidates, might be further developed as selective anti-telomerase reagents...
  2. ncbi Telomerase targeted oligonucleotide thio-phosphoramidates in T24-luc bladder cancer cells
    Z Gunnur Dikmen
    Faculty of Medicine, Department of Biochemistry, University of Hacettepe, Ankara, Turkey
    J Cell Biochem 104:444-52. 2008
    ..The obtained results warrant further in vivo evaluation of GRN163L as a potential treatment for bladder cancer...
  3. pmc RNA mimetics: oligoribonucleotide N3'-->P5' phosphoramidates
    S M Gryaznov
    Lynx Therapeutics Inc, 3832 Bay Center Place, Hayward, CA 94545, USA
    Nucleic Acids Res 26:4160-7. 1998
    ..The properties of the oligoribonucleotide N3'-->P5' phosphoramidates indicate that these compounds can be used as hydrolytically stable structural and functional RNA mimetics...
  4. ncbi Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent
    Sergei M Gryaznov
    Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA
    Nucleosides Nucleotides Nucleic Acids 26:1577-9. 2007
    ..GRN163L is currently in Phase I and Phase I/II clinical studies in patients with solid tumors and CLL, respectively...
  5. doi Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents
    Sergei M Gryaznov
    Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA
    Chem Biodivers 7:477-93. 2010
    ..This compound is currently in multiple Phase-I and Phase-I/II clinical trials as potential broad-spectrum anticancer agent...
  6. ncbi Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents
    Sergei Gryaznov
    Geron Corporation, Menlo Park, California 94025, USA
    Nucleosides Nucleotides Nucleic Acids 22:577-81. 2003
    ..Telomerase inhibition by GRN163 produced gradual telomere shortening, followed by cellular senescence and/or apoptosis of cancer derived cell lines...
  7. ncbi Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents
    S M Gryaznov
    Geron Corporation, Menlo Park, CA 94025, USA
    Biochim Biophys Acta 1489:131-40. 1999
    ..Finally, the oligo-2'-deoxyphosphoramidate double stranded complexes can structurally mimic native RNA complexes, which could be efficiently and specifically recognized by the RNA binding proteins, such as HIV-1 Rev and Tat...
  8. ncbi Novel short oligonucleotide conjugates as inhibitors of human telomerase
    Krisztina Pongracz
    Geron Corporation, Menlo Park, California 94025, USA
    Nucleosides Nucleotides Nucleic Acids 22:1627-9. 2003
    ....
  9. pmc New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
    Rintaro Hashizume
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Neuro Oncol 10:112-20. 2008
    ..These data support further development of intranasal delivery of tumor-specific therapeutic agents for brain tumor patients...
  10. ncbi Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase
    Shalmica R Jackson
    Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Cancer Res 67:1121-9. 2007
    ....
  11. ncbi Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells
    Jaime Gomez-Millan
    Department of Radiation Oncology, Radiation and Cancer Biology Laboratory, Indiana University School of Medicine, Indianapolis, IN 46202 5251, USA
    Int J Radiat Oncol Biol Phys 67:897-905. 2007
    ..Our goal was to test whether the treatment with GRN163L enhances sensitivity to irradiation (IR) in MDA-MB-231 breast cancer cells...
  12. ncbi Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition
    Brittney Shea Herbert
    Department of Cell Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9039, USA
    Oncogene 24:5262-8. 2005
    ..These results suggest that the lipid-conjugated thio-phosphoramidates could be important for improved pharmacodynamics of telomerase inhibitors in cancer therapy...
  13. pmc Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts
    Tomoko Ozawa
    Brain Tumor Research Center of the Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Neuro Oncol 6:218-26. 2004
    ..These findings support further development of this compound as a potential anticancer agent...
  14. ncbi Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer
    Amelia E Hochreiter
    Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202 5251, USA
    Clin Cancer Res 12:3184-92. 2006
    ..The aim of this study was to address the breast cancer translational potential of the novel telomerase inhibitor, GRN163L...